Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moleculin Biotech (MBRX) Total Non-Current Liabilities (2016 - 2025)

Moleculin Biotech's Total Non-Current Liabilities history spans 10 years, with the latest figure at $7.1 million for Q4 2025.

  • Quarterly results put Total Non-Current Liabilities at $7.1 million for Q4 2025, up 23.77% from a year ago — trailing twelve months through Dec 2025 was $7.1 million (up 23.77% YoY), and the annual figure for FY2025 was $7.1 million, up 23.77%.
  • Total Non-Current Liabilities for Q4 2025 was $7.1 million at Moleculin Biotech, up from $5.9 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $8.2 million in Q2 2025 to a low of $3.4 million in Q2 2021.
  • The 5-year median for Total Non-Current Liabilities is $5.9 million (2024), against an average of $5.7 million.
  • The sharpest move saw Total Non-Current Liabilities skyrocketed 81.39% in 2022, then tumbled 34.83% in 2023.
  • Year by year, Total Non-Current Liabilities stood at $3.7 million in 2021, then skyrocketed by 39.86% to $5.2 million in 2022, then skyrocketed by 41.42% to $7.3 million in 2023, then dropped by 21.57% to $5.7 million in 2024, then increased by 23.77% to $7.1 million in 2025.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods came in at $7.1 million, $5.9 million, and $8.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.